Physician profile
Mary Dea
NPI 1518951474
$1,358.89
in general payments reported to CMS, 2019-2025
21 companies · $899 in 2025
The $899 reported for 2025 was more than what 83% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $460 · 2025: $899.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,359.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,358.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $170.92 | 2024-2025 | Ozempic, Rybelsus |
| Verity Pharmaceuticals INC. | $146.93 | 2024-2025 | Tlando |
| Lilly USA, LLC | $134.93 | 2024-2025 | Zepbound, Mounjaro |
| Bayer Healthcare Pharmaceuticals INC. | $119.35 | 2024-2025 | |
| Exact Sciences Corporation | $96.45 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Abbvie INC. | $95.89 | 2024-2025 | |
| Xeris Pharmaceuticals, INC. | $86.84 | 2024-2025 | Recorlev, Gvoke Hypopen |
| Astrazeneca Pharmaceuticals LP | $74.57 | 2024-2025 | Airsupra, Farxiga |
| E.R. Squibb & Sons, L.L.C. | $61.20 | 2024-2025 | Camzyos, Eliquis |
| Otsuka America Pharmaceutical, INC. | $57.35 | 2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $44.15 | 2024 | Caplyta |
| Axsome Therapeutics, INC. | $40.75 | 2025 | Auvelity |
| Glaxosmithkline, LLC. | $37.33 | 2025 | Trelegy Ellipta |
| Amgen INC. | $35.09 | 2025 | Repatha, Otezla |
| Janssen Pharmaceuticals, INC | $31.50 | 2024 | Spravato |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $25.49 | 2024 | Symplicity G3 |
| Radius Health, INC. | $24.55 | 2025 | Tymlos |
| Corcept Therapeutics | $23.69 | 2025 | Korlym |
| Phathom Pharmaceuticals, INC. | $20.37 | 2025 | Voquezna |
| Pfizer INC. | $17.30 | 2025 | |
| Antares Pharma, INC. | $14.24 | 2025 | Xyosted |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Dea listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.